Glucagon-like peptide-1 receptor agonists to treat chronic liver disease: real-world evidence or ambiguity?
- PMID: 38499341
- DOI: 10.1136/gutjnl-2024-331976
Glucagon-like peptide-1 receptor agonists to treat chronic liver disease: real-world evidence or ambiguity?
Keywords: GLUCAGON-LIKE PEPTIDES.
Conflict of interest statement
Competing interests: SS attended scientific advisory committee meetings or received speaking fees from AstraZeneca, Atara, Boehringer Ingelheim, Bristol Myers Squibb, Merck, Novartis, Panalgo, Pfizer and Seqirus. RH is an Editorial Board Member for Gut journal.
Comment on
-
Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes.Gut. 2024 Apr 5;73(5):835-843. doi: 10.1136/gutjnl-2023-330962. Gut. 2024. PMID: 38253482 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources